CN115103689A - 用于药物递送的树枝状大分子组合物和方法 - Google Patents

用于药物递送的树枝状大分子组合物和方法 Download PDF

Info

Publication number
CN115103689A
CN115103689A CN202080095453.0A CN202080095453A CN115103689A CN 115103689 A CN115103689 A CN 115103689A CN 202080095453 A CN202080095453 A CN 202080095453A CN 115103689 A CN115103689 A CN 115103689A
Authority
CN
China
Prior art keywords
composition
dendrimer
inhibitors
tumor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095453.0A
Other languages
English (en)
Chinese (zh)
Inventor
J.克莱兰德
R.夏尔马
M.孙
S.阿皮亚尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ashwata Therapeutics Co ltd
Original Assignee
Ashwata Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashwata Therapeutics Co ltd filed Critical Ashwata Therapeutics Co ltd
Publication of CN115103689A publication Critical patent/CN115103689A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202080095453.0A 2019-12-04 2020-12-04 用于药物递送的树枝状大分子组合物和方法 Pending CN115103689A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962943705P 2019-12-04 2019-12-04
US62/943,705 2019-12-04
US202063108186P 2020-10-30 2020-10-30
US63/108,186 2020-10-30
PCT/US2020/063332 WO2021113651A2 (en) 2019-12-04 2020-12-04 Dendrimer compositions and methods for drug delivery

Publications (1)

Publication Number Publication Date
CN115103689A true CN115103689A (zh) 2022-09-23

Family

ID=74104190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095453.0A Pending CN115103689A (zh) 2019-12-04 2020-12-04 用于药物递送的树枝状大分子组合物和方法

Country Status (9)

Country Link
US (3) US20230226199A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069307A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023504286A (cg-RX-API-DMAC7.html)
CN (1) CN115103689A (cg-RX-API-DMAC7.html)
AU (1) AU2020397063A1 (cg-RX-API-DMAC7.html)
CA (1) CA3163886A1 (cg-RX-API-DMAC7.html)
IL (1) IL293604A (cg-RX-API-DMAC7.html)
PH (1) PH12022551368A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021113651A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116196292A (zh) * 2023-02-16 2023-06-02 东华大学 一种靶向肽修饰的聚酰胺-胺树状大分子复合纳米材料及其制备方法
CN118108799A (zh) * 2024-04-29 2024-05-31 内蒙古工业大学 基于DMXAA的含Se多肽药物及其制备方法和应用
CN118846078A (zh) * 2024-07-02 2024-10-29 中国人民解放军空军军医大学 Ndrg2基因联合分子靶向抑制剂在制备肾细胞癌治疗药物中的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
JP2023522984A (ja) 2020-04-24 2023-06-01 アシュバッタ セラピューティクス, インコーポレイテッド 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
PH12023550133A1 (en) * 2020-07-17 2024-06-24 Ashvattha Therapeutics Inc Dendrimer compositions and methods for drug delivery to injured kidney
JP2023549081A (ja) * 2020-10-30 2023-11-22 アシュバッタ セラピューティクス, インコーポレイテッド Petイメージングおよび放射線療法のための放射標識エーテルデンドリマーコンジュゲート
WO2022192135A1 (en) * 2021-03-08 2022-09-15 Transdermal Biotechnology, Inc. Dendrimer-n-actyl-l-cysteine conjugates for treatment or prevention of aging skin or other indications
TW202313118A (zh) * 2021-06-10 2023-04-01 美商阿什瓦塔治療股份有限公司 樹枝狀體結合物及其使用方法
EP4490158A4 (en) * 2022-03-10 2026-01-07 Curators Of The University Of Missouri The NEW PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS CONTAINING IT, METHODS OF MANUFACTURING IT AND METHODS OF TREATING A DISEASE
WO2023183367A1 (en) * 2022-03-22 2023-09-28 Board Of Regents Of The University Of Nebraska Metformin nanoformulations and methods of use thereof
EP4496568A1 (en) * 2022-03-22 2025-01-29 Board of Regents of the University of Nebraska Metformin nanoformulations and methods of use thereof
CN114796492B (zh) * 2022-05-12 2023-01-13 大连理工大学 一种超声驱动纳米声敏疫苗及其制备和应用
WO2025183982A1 (en) * 2024-02-28 2025-09-04 Washington State University Psma-targeted dendrimer nanoplatform for cancer detection and therapy
WO2025226820A1 (en) * 2024-04-23 2025-10-30 Ashvattha Therapeutics, Inc. Csf1r inhibitor dendrimer conjugates and uses thereof
WO2025259214A1 (en) 2024-06-14 2025-12-18 EGE Kimya San. ve Tic. A.S. Use of dendrimer compounds as anti-skinning agents
WO2025259215A1 (en) 2024-06-14 2025-12-18 EGE Kimya San. ve Tic. A.S. Use of dendrimer compounds as complexing ligands for metal activity enhancement

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046446A2 (en) * 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
US20140371401A1 (en) * 2013-06-17 2014-12-18 Universidad De Talca Pamam, spacer molecule and cafestol polymers
WO2015168347A1 (en) * 2014-04-30 2015-11-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
WO2016025741A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016025745A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Dendrimer compositions and use in treatment of neurological and cns disorders
US20170119897A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
WO2019094952A1 (en) * 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856807A (en) 1972-03-13 1974-12-24 Upjohn Co L-({60 s,5s)-{60 -amino-3-chloro-2-isoxazoline-5-acetic acid
US3878047A (en) 1973-02-02 1975-04-15 Upjohn Co Process for production of AT-125
US5087639A (en) 1988-11-02 1992-02-11 The Upjohn Company Preventing CNS toxicity of acivicin when used with four large neutral amino acids
CA2786794C (en) * 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
CA2767163A1 (en) 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
WO2011123591A1 (en) 2010-03-31 2011-10-06 Wayne State University Injectable dendrimer hydrogel nanoparticles
ES2910550T3 (es) * 2014-05-21 2022-05-12 Icd Therapeutics Gmbh Conjugados terapéuticos con dendrímeros sulfatados para selección de objetivos intracelulares
MX2017007873A (es) * 2014-12-15 2017-11-06 Univ Johns Hopkins Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares.
KR101918346B1 (ko) * 2015-05-06 2018-11-13 경북대학교 산학협력단 난용성 활성물질의 수용성 덴드리머 복합체
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
US12290571B2 (en) * 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
WO2020132196A1 (en) * 2018-12-21 2020-06-25 Tiba Biotech Llc Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same
WO2021113662A2 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046446A2 (en) * 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
US20140371401A1 (en) * 2013-06-17 2014-12-18 Universidad De Talca Pamam, spacer molecule and cafestol polymers
WO2015168347A1 (en) * 2014-04-30 2015-11-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
WO2016025741A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016025745A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Dendrimer compositions and use in treatment of neurological and cns disorders
US20170119897A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
WO2019094952A1 (en) * 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
US20190142964A1 (en) * 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHUGO YAMASHITA等: "Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis", JOURNAL OF DRUG TARGETING, vol. 26, no. 9, pages 818 - 828 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116196292A (zh) * 2023-02-16 2023-06-02 东华大学 一种靶向肽修饰的聚酰胺-胺树状大分子复合纳米材料及其制备方法
CN118108799A (zh) * 2024-04-29 2024-05-31 内蒙古工业大学 基于DMXAA的含Se多肽药物及其制备方法和应用
CN118846078A (zh) * 2024-07-02 2024-10-29 中国人民解放军空军军医大学 Ndrg2基因联合分子靶向抑制剂在制备肾细胞癌治疗药物中的应用

Also Published As

Publication number Publication date
US20210170040A1 (en) 2021-06-10
US20230226199A1 (en) 2023-07-20
PH12022551368A1 (en) 2023-05-08
IL293604A (en) 2022-08-01
CA3163886A1 (en) 2021-06-10
JP2023504286A (ja) 2023-02-02
AU2020397063A1 (en) 2022-07-07
US20230372499A1 (en) 2023-11-23
WO2021113651A3 (en) 2021-08-26
EP4069307A2 (en) 2022-10-12
WO2021113651A2 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
US20230372499A1 (en) Dendrimer compositions and methods for drug delivery
TW202108179A (zh) 細胞毒性劑經由支鏈連接子與細胞結合分子的偶聯物
JP7719072B2 (ja) 三分岐n-アセチルガラクトサミン修飾ヒドロキシルポリアミドアミンデンドリマーおよびその使用方法
WO2025247082A1 (en) An antibody-drug conjugate having two or more different functional small molecules for enhanced treatment of refractory diseases.
CN119158034A (zh) 特异于结合素-4的双环肽配体
ES2863369T3 (es) Terapias inmunoablativas
ES2653887T3 (es) Procedimiento para aumentar el efecto inmunológico
JP2021523151A (ja) 負の表面電荷を有するマイクロ粒子及びナノ粒子
KR20210024065A (ko) 아연 제제를 이용한 종양학 치료
US12303724B2 (en) Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer
WO2022187631A1 (en) Micelle releasing thermosensitive hydrogels as a therapeutic delivery system
US20240026294A1 (en) Nanoparticle-mediated immune cell manufacture and use thereof
HK40081468A (en) Dendrimer compositions and methods for drug delivery
Zuo et al. H-ferritin engineered nanoplatform reprograms metabolism and immunity for glioblastoma immunotherapy
US20230381349A1 (en) Methods and compositions for imaging and treating cancer
WO2026046110A1 (zh) 一种基于工程化红细胞的新型药物递送系统
TW202608449A (zh) 替拉紮明(tirapazamine)組合物及方法
WO2024196783A1 (en) Bioengineered colon-specific immune niche for the treatment of ulcerative colitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081468

Country of ref document: HK